Evonile Pharma Q2 FY27: First Results After Novartis Exit
Evonile Pharma, formerly Novartis India, posted Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore as it builds its own field force.
BRANDED-GENERICS
Jagsonpal Q2 FY27 Revenue Rises 29% to ₹96.4 Crore as Aequitas Deal Opens Hospital Channel
Jagsonpal Pharmaceuticals’ consolidated Q2 FY27 revenue rose 29% to ₹96.4 crore as Aequitas Healthcare was consolidated for the first time, while the company said it expects quarterly revenue to cross ₹100 crore in Q3 after adding Group Pharma’s wellness portfolio.
Strides Strengthens Africa Business with Acquisition of Branded Generics from Sandoz
Strides Pharma Science Limited announced that its step-down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with […]
